Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. (December 2016)

• Record Type: Journal Article
• Authors: Kuramitsu, Shunichiro; Yamamichi, Akane; Ohka, Fumiharu; Motomura, Kazuya; Hara, Masahito; Natsume, Atsushi
• Is Part Of: Immunotherapy. Volume 8:Number 12(2016:Dec.)
• Page Start: 1393
• Page End: 1404
• Publication Date: 2016-12
• Subjects: chimeric antigen receptor T cells -- glioblastoma -- immune modulators -- T cell receptor gene-modified T cells; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2016-0076
• Languages: English
• ISSNs: 1750-743X

Abstract

Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed.